China Pharma Holdings, Inc. (CPHI): R&D Expense
$280.9K
Year ended 2025-12-31
$333.3K
Trailing 12 months to 2026-06-30
+14.8%
3-year compound annual growth
-5.8%
5-year compound annual growth
-11.6%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $280.9K | -1.1% | 2026-04-01, From 2025-01-01 |
| 2024-12-31 | $283.9K | +18.3% | 2026-04-01, From 2024-01-01 |
| 2023-12-31 | $240.1K | +29.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $185.9K | -41.7% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $319.0K | -15.6% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $378.0K | +64.6% | 2022-03-30, From 2020-01-01 |
| 2019-12-31 | $229.6K | +33.2% | 2021-03-26, From 2019-01-01 |
| 2018-12-31 | $172.4K | +90.5% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $90.5K | -75.3% | 2019-03-28, From 2017-01-01 |
| 2016-12-31 | $366.0K | -62.0% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $961.9K | -65.6% | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $2.80M | +66.3% | 2015-12-28, From 2014-01-01 |
| 2013-12-31 | $1.68M | +283.7% | 2015-12-28, From 2013-01-01 |
| 2012-12-31 | $438.7K | n/a | 2014-03-20, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $280.9K | -1.1% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $21.82M | +16.1% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $107.0K | -82.0% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $11.80M | -12.4% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $38.20M | -1.6% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $10.38M | +43.7% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $3.07M | -6.8% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $136.81M | +117.3% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $58.03M | +28.7% |
Compare CPHI, CRVO, PRPH, MRKR side by side · Screen every company in Pharmaceutical Preparations ↗